ATE95065T1 - Methode und mittel zur vorbeugenden behandlung von autoimmunkrankheiten. - Google Patents

Methode und mittel zur vorbeugenden behandlung von autoimmunkrankheiten.

Info

Publication number
ATE95065T1
ATE95065T1 AT88303198T AT88303198T ATE95065T1 AT E95065 T1 ATE95065 T1 AT E95065T1 AT 88303198 T AT88303198 T AT 88303198T AT 88303198 T AT88303198 T AT 88303198T AT E95065 T1 ATE95065 T1 AT E95065T1
Authority
AT
Austria
Prior art keywords
autoimmune disease
susceptibility
allele
antigen
antigens
Prior art date
Application number
AT88303198T
Other languages
English (en)
Inventor
John Todd
John I Bell
Hans Acha-Orbea
Hugh O Mcdevitt
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Application granted granted Critical
Publication of ATE95065T1 publication Critical patent/ATE95065T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT88303198T 1987-04-09 1988-04-11 Methode und mittel zur vorbeugenden behandlung von autoimmunkrankheiten. ATE95065T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3637287A 1987-04-09 1987-04-09
EP88303198A EP0286447B1 (de) 1987-04-09 1988-04-11 Methode und Mittel zur vorbeugenden Behandlung von Autoimmunkrankheiten

Publications (1)

Publication Number Publication Date
ATE95065T1 true ATE95065T1 (de) 1993-10-15

Family

ID=21888256

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88303198T ATE95065T1 (de) 1987-04-09 1988-04-11 Methode und mittel zur vorbeugenden behandlung von autoimmunkrankheiten.

Country Status (5)

Country Link
EP (1) EP0286447B1 (de)
JP (1) JPS6434924A (de)
AT (1) ATE95065T1 (de)
CA (1) CA1327162C (de)
DE (1) DE3884440T2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194425A (en) * 1988-06-23 1993-03-16 Anergen, Inc. Mhc-mediated toxic conjugates useful in ameliorating autoimmunity
NO306996B1 (no) * 1989-02-17 2000-01-24 Bayer Ag Isolert bukspyttkjerteloey-celle-(ICA)-antigen for in vitro- bruk
IL89431A0 (en) * 1989-02-27 1989-09-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of autoimmune diseases
EP0474764A4 (en) * 1989-05-31 1992-11-19 Scripps Clinic And Research Foundation Method to treat rheumatoid arthritis
US5230887A (en) * 1990-07-11 1993-07-27 Immune Network Research Ltd. Immune system stabilizers for prevention and therapy of disorders associated with immune system disfunction
EP0674526B1 (de) * 1992-12-17 2003-05-07 SRIRAM, Subramaniam Impfung mit peptiden von mhc klasse ii molekülen zur behandlung von autoimmunkrankheiten
US6045796A (en) * 1992-12-17 2000-04-04 Anergen, Inc. Vaccination with peptide of MHC class II molecules for treatment of autoimmune disease
AU713067B2 (en) * 1996-04-03 1999-11-25 Anergen, Inc. Cyclic peptide vaccines for treatment and prevention of diabetes
AU2001253219A1 (en) * 2000-04-04 2001-10-15 Corixa Corporation Composition for treatment of autoimmune disease
BRPI0113400B1 (pt) 2000-08-21 2018-05-15 Apitope Technology Bristol Método para seleção de peptídeo
EP1684202A4 (de) * 2003-10-15 2007-10-03 Signpost Corp Verfahren zur bestimmung eines genetischen polymorphismus zur beurteilung eines grades der krankheitsgefahr, verfahren zur beurteilung des grades der krankheitsgefahr und beurteilungs-array

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751181A (en) * 1984-12-31 1988-06-14 Duke University Methods and compositions useful in the diagnosis and treatment of autoimmune diseases
WO1986007464A1 (en) * 1985-06-14 1986-12-18 Genetic Systems Corporation Methods for identifying alleles associated with increased risk of diabetes

Also Published As

Publication number Publication date
CA1327162C (en) 1994-02-22
JPS6434924A (en) 1989-02-06
EP0286447A2 (de) 1988-10-12
DE3884440T2 (de) 1994-04-28
EP0286447B1 (de) 1993-09-29
EP0286447A3 (en) 1989-09-27
DE3884440D1 (de) 1993-11-04

Similar Documents

Publication Publication Date Title
RU2138512C1 (ru) Вакцина для профилактики или лечения опосредованной т-клетками патологии или нерегулируемой репликации клонами т-клеток, способ выделения вакцины, способ диагностирования или прогнозирования восприимчивости к ревматоидному артриту или рассеянному склерозу, способ профилактики или лечения ревматоидного артрита или рассеянного склероза и содержащий последовательность sgdqggne пептид, являющийся агентом для обнаружения, профилактики или лечения рассеянного склероза
Deng et al. Determinant capture as a possible mechanism of protection afforded by major histocompatibility complex class II molecules in autoimmune disease.
ES2278463T3 (es) Metodo para reducir la inmunogenicidad de proteinas.
KR960703014A (ko) Mhc 분자 hla-c-클론 10과 복합체를 형성하는 분리된 펩티드 및 그것의 사용(isolated peptides which form complexes with mhc molecule hla-c-clone 10 and uses thereof)
ATE95065T1 (de) Methode und mittel zur vorbeugenden behandlung von autoimmunkrankheiten.
DK203489D0 (da) Anti-t-celle receptor determinanter til diagnosticering og behandling af autoimmune sygdomme
ATE106454T1 (de) Kennzeichnung und nachweis von mit autoimmunkrankheiten assoziierten sequenzen.
SHIN et al. Molecular cloning and characterization of a gene encoding a 13.1 kDa antigenic protein of Naegleria fowleri
Nicholson et al. BALB/c substrain differences in susceptibility to Theiler's murine encephalomyelitis virus-induced demyelinating disease
NO960858L (no) Anvendelser av myelin - oligodendrocyt-glykoprotein og peptid-deler derav i metoder i forbindelse med autoimmunsykdom
CA2049921C (en) Allergenic proteins from ragweed and uses therefor
Moore et al. Cerebrospinal meningitis epidemics
Sestak et al. Variability among Cryptosporidium parvum genotype 1 and 2 immunodominant surface glycoproteins
US5698204A (en) Recombinant allergenic proteins from ragweed pollen
Reitan et al. The primary IgM antibody repertoire: a source of potent idiotype immunogens
Araga et al. A complementary peptide vaccine that induces T cell anergy and prevents experimental allergic neuritis in Lewis rats
Abraham et al. NOD background genes influence T cell responses to GAD 65 in HLA-DQ8 transgenic mice
DE69332956D1 (de) Impfung mit peptiden von mhc klasse ii molekülen zur behandlung von autoimmunkrankheiten
ATE219513T1 (de) Molekulares klonieren von genomischen und cdna- sequenzen, die für zelluläre rezeptoren für poliovirus kodieren
US5891439A (en) Lymphocyte stimulating factor
Holbrook et al. Tolerization as a tool for generating novel monoclonal antibodies
OFFNER et al. Prevention, suppression, and treatment of experimental autoimmune encephalomyelitis with a synthetic T cell receptor V region peptide
Bakela et al. Rescue of autoimmune hepatitis by soluble MHC class II molecules in an altered concanavalin A‐induced experimental model
Rumyantsev The origin of individual differences in the course and severity of diseases
Leung Characterization of the pathogenesis of amelanosis in the Smyth line chicken: A model of the human autoimmune disease vitiligo

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties